Bera hf.: Afkomutilkynning fyrir 1. mars 2026 til 31. ágúst 2026

Bera reported Q2 2026 sales growth of 21.0%, EBITDA of ISK 2,452 million, up 52% year over year, and after-tax profit of ISK 1,419 million, up from ISK 875 million. It raised its full-year EBITDA forecast to ISK 6,300–6,600 million; first-half EBITDA rose 42% to ISK 3,677 million, while net interest-bearing debt/EBITDA fell to 1.9 from 2.6. The company also reported a planned ISK 4,550 million annual investment program and committed to limiting year-end increases in subsidiary-produced goods to 2.5%.

Analysis

The earnings beat is stronger than a pure acquisition story, but not yet clean evidence of a durable step-up in organic earnings. Newly consolidated Gæðabakstur and Kjarnavörur account for 334m kr. of the 841m kr. Q2 EBITDA increase; the remaining uplift came from the other reported segments, led by Ölgerðin and lower Collab export losses. The key quality test is whether core growth and cost control hold after the acquired businesses are fully in the comparison base.

Near term, the raised full-year EBITDA range supports sentiment. The counterweight is the announced 2.5% ceiling on year-end price increases for manufactured products: it may support labor-market stability and demand, but could cap pricing recovery if wages or inputs rise faster. Q2 payroll costs grew materially faster than sales, so margin durability matters more than headline revenue growth. The króna-driven price reductions on imported goods also benefit customers but may make further price-led growth harder.

Over 1–3 months, monitor the December results, the labor agreement outcome, and competition approval for the Bakkus transaction. Its stated annual EBITDA of about 100m kr. against 438m kr. consideration is attractive on the company’s estimate, but approval, integration, and realized earnings remain unverified. Over 6–18 months, the planned 4.55bn kr. capex program and Iceland Spring capacity expansion could unlock growth, while absorbing cash; lower leverage is encouraging but partly reflects acquired EBITDA entering the denominator. The 9.6% average ISK debt cost leaves refinancing and cash-generation sensitivity. The thesis weakens if guidance is cut, organic segment EBITDA stalls, or leverage rises as investment peaks.

Key Decisions for Investors

• Maintain a positive but valuation-disciplined bias to Bera; do not chase the initial earnings reaction without checking the share-price move and valuation, which are not supplied here. No ticker was provided, so do not infer one.
• Treat the raised guidance as a catalyst, not confirmation: track Q3 organic EBITDA excluding the acquired businesses and watch payroll and gross-margin trends. Reassess if the next report shows core EBITDA weakening or guidance is reduced.
• Monitor the 2.5% price-increase commitment against wage settlements and input costs. A widening gap between cost inflation and realized pricing would be a downside trigger; stable margins despite the constraint would strengthen the quality-of-earnings case.
• Keep the Bakkus deal and capex program on a watchlist rather than underwriting forecast returns now. Verify competition approval, purchase terms, delivered EBITDA, and post-investment net debt before increasing exposure.